ChromaDex amends ATM sales agreement; adds Roth Capital, removes B. Riley

Niagen Bioscience, Inc.

Amendment dated Nov 20, 2024 to existing At Market Issuance Sales Agreement of June 12, 2020.
Roth Capital Partners added as Sales Agent; B. Riley Securities removed.
Raymond James & Associates and Roth Capital Partners remain as the two Sales Agents.
No changes to the $0.001 par value common stock or ATM program terms beyond agent roster.
Agreement governs at-the-market equity offering program for ChromaDex common stock.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.